Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases
Angewandte Chemie International Edition · 2024
DOI: 10.1002/anie.202411037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2024. Verfasst von Wen Shuai und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, Innovation Center of Nursing Research, West China Hospital, Sichuan University, No. 17, Section…. Hauptthemen laut MEDLINE: Mitogen-Activated Protein Kinase 10, Parkinson Disease, Protein Kinase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National funded postdoctoral research program, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
c‐Jun N‐terminal kinases (JNKs) including JNK1/2/3 are key members of mitogen‐activated protein kinase family. Wherein JNK3 is specifically expressed in brain and emerges as therapeutic target, especially for neurodegenerative diseases. However, developing JNK3 selective inhibitors as chemical probes to investigate its therapeutic potential in diseases remains challenging. Here, we adopted the covalent strategy for identifying JNK3‐selective covalent inhibitor JC16I , with high inhibitory activity against JNK3. Despite targeting a conserved cysteine in the vicinity of ATP pocket in JNK family, JC16I exerted a greater than 160‐fold selectivity for JNK3 over JNK1/2. Importantly, even at low concentration, JC16I showed enhanced and long‐lasting inhibition against cellular JNK3. In addition, its alkyne‐containing probe JC‐P1 could label JNK3 in SH‐SY5Y cell lysate and living cells, with good proteome‐wide selectivity. JC16I selectively suppressed the abnormal activation of JNK3 signaling and sufficiently exhibited neuroprotective effect in Parkinson's diseases (PD) models. Overall, our findings highlight the potential of developing isoform‐selective and cell‐active JNK3 inhibitors by covalent drug design strategy targeting a conserved cysteine. This work not only provides a valuable chemical probe for JNK3‐targeted investigations in vitro and in vivo but also opens new avenues for the treatment of PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, Innovation Center of Nursing Research, West China Hospital, Sichuan University, No. 17, Section 3, Renmin South Road, 610041, Chengdu, China.
ORCID-Profile: Liang Ouyang
Förderung
- National Natural Science Foundation of China
- National funded postdoctoral research program
- Natural Science Foundation of Sichuan Province
- Sichuan University Science Research Foundation
- Postdoctoral Research Foundation of China
- Postdoctor Research Fund of West China Hospital, Sichuan University
- the Foundation for Innovative Research Groups of the Natural Science Foundation of Sichuan Provinve
Zitieren
APA
Shuai, W., Yang, P., Xiao, H., Zhu, Y., Bu, F., Wang, A., Sun, Q., Wang, G., & Ouyang, L. (2024). Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202411037
Vancouver
Shuai W, Yang P, Xiao H, Zhu Y, Bu F, Wang A, et al. Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases. Angewandte Chemie International Edition. 2024. doi:10.1002/anie.202411037
BibTeX
@article{Shuai2024,
author = {Shuai, Wen and Yang, Panpan and Xiao, Huan and Zhu, Yumeng and Bu, Faqian and Wang, Aoxue and Sun, Qiu and Wang, Guan and Ouyang, Liang},
title = {Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases},
journal = {Angewandte Chemie International Edition},
year = {2024},
doi = {10.1002/anie.202411037}
}
EUVIMED